J
Judith Dierlamm
Researcher at University of Hamburg
Publications - 132
Citations - 6457
Judith Dierlamm is an academic researcher from University of Hamburg. The author has contributed to research in topics: Fluorescence in situ hybridization & Lymphoma. The author has an hindex of 35, co-authored 123 publications receiving 5976 citations. Previous affiliations of Judith Dierlamm include Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling
Michael Hummel,Stefan Bentink,Hilmar Berger,Wolfram Klapper,Swen Wessendorf,Thomas F. E. Barth,Heinz Wolfram Bernd,Sergio Cogliatti,Judith Dierlamm,Alfred C. Feller,Martin-Leo Hansmann,Eugenia Haralambieva,Lana Harder,Dirk Hasenclever,Michael Kühn,Dido Lenze,Peter Lichter,José I. Martín-Subero,Peter Möller,Hans Konrad Müller-Hermelink,German Ott,Reza Parwaresch,Christiane Pott,Andreas Rosenwald,Maciej Rosolowski,Carsten Schwaenen,Benjamin Stürzenhofecker,Monika Szczepanowski,Heiko Trautmann,Hans Heinrich Wacker,Rainer Spang,Markus Loeffler,Lorenz Trümper,Harald Stein,Reiner Siebert +34 more
TL;DR: The molecular definition of Burkitt's lymphoma clarifies and extends the spectrum of the WHO criteria for Burkitt’s lymphoma.
Journal ArticleDOI
The Apoptosis Inhibitor Gene API2 and a Novel 18q Gene,MLT, Are Recurrently Rearranged in the t(11;18)(q21;q21) Associated With Mucosa-Associated Lymphoid Tissue Lymphomas
Judith Dierlamm,Mathijs Baens,Iwona Wlodarska,Margarita Stefanova-Ouzounova,Jesús M. Hernández,Dieter K. Hossfeld,Christiane De Wolf-Peeters,Anne Hagemeijer,Herman Van den Berghe,Peter Marynen +9 more
TL;DR: It is shown that the API2 gene, encoding an inhibitor of apoptosis also known as c-IAP2, HIAP1, and MIHC, and a novel gene on 18q21 characterized by several Ig-like C2-type domains, named MLT, are recurrently rearranged in the t(11;18).
Journal ArticleDOI
T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma.
Berthold Streubel,Andrea Lamprecht,Judith Dierlamm,Lorenzo Cerroni,Manfred Stolte,German Ott,Markus Raderer,Andreas Chott +7 more
TL;DR: IGH is identified as a new translocation partner of MALT1 in MALT lymphomas, which tend to arise frequently at sites other than the gastrointestinal tract and lung.
Journal ArticleDOI
Accelerated and safe expansion of human mesenchymal stromal cells in animal serum‐free medium for transplantation and regenerative medicine
Claudia Lange,Figen Cakiroglu,Andrej-Nikolai Spiess,Heike Cappallo-Obermann,Judith Dierlamm,Axel R. Zander +5 more
TL;DR: A GMP‐compatible protocol for safe and accelerated expansion of hMSC to be used in cell and tissue therapy and gene expression profiles show increased mRNA levels of genes involved in cell cycle and DNA replication and downregulation of developmental and differentiation genes, supporting the observation of increased MSC‐expansion in PL‐supplemented medium.
Journal ArticleDOI
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
Peter Borchmann,Helen Goergen,Carsten Kobe,Andreas Lohri,Richard Greil,Dennis A. Eichenauer,Josée M. Zijlstra,Jana Markova,Julia Meissner,Michaela Feuring-Buske,Andreas Hüttmann,Judith Dierlamm,Martin Soekler,Hans Joachim Beck,Wolfgang Willenbacher,Wolf-Dieter Ludwig,Thomas Pabst,Max S. Topp,Felicitas Hitz,Martin Bentz,Ulrich Keller,Dagmar Kühnhardt,Helmut Ostermann,Norbert Schmitz,Bernd Hertenstein,Walter E. Aulitzky,Georg Maschmeyer,Tom Vieler,Hans Theodor Eich,Christian Baues,Harald Stein,Michael Fuchs,Georg Kuhnert,Volker Diehl,Markus Dietlein,Andreas Engert +35 more
TL;DR: This open-label, randomised, parallel-group phase 3 trial investigated whether metabolic response determined by PET after two cycles of standard regimen eBEACOPP (PET-2) would allow adaption of treatment intensity, increasing it for PET-2-positive patients and reducing it forPET- 2-negative patients and showed non-inferiority in the 5-year progression-free survival estimates.